Galectin Therapeutics Inc. is a biotechnology company that is focused on the development of therapies for fibrotic diseases and cancer. The company's lead product candidate is called belapectin (formerly known as GR-MD-02), which is a carbohydrate-based drug that targets galectin proteins.
Galectin proteins are involved in a range of cellular processes, including inflammation and fibrosis. By targeting galectin proteins, belapectin has the potential to treat a variety of fibrotic diseases, including nonalcoholic steatohepatitis (NASH), liver fibrosis, and pulmonary fibrosis.
In addition to belapectin, Galectin Therapeutics is also developing a pipeline of other drug candidates, including compounds for the treatment of cancer and other diseases.
Overall, Galectin Therapeutics is focused on developing innovative therapies that address unmet medical needs in areas such as fibrosis and cancer. The company is committed to advancing the science of galectin biology and developing new treatments that can improve the lives of patients.
- Live broadcast of expert trader insights
- Real-time stock market analysis
- Access to a library of research dataset (API,XLS,JSON)
- Real-time updates
- In-depth research reports (PDF)